Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Research output: Contribution to journalJournal articlepeer-review

  • Antoinette Moran
  • Brian Bundy
  • Dorothy J Becker
  • Linda A DiMeglio
  • Stephen E Gitelman
  • Robin Goland
  • Carla J Greenbaum
  • Kevan C Herold
  • Jennifer B Marks
  • Philip Raskin
  • Srinath Sanda
  • Desmond Schatz
  • Diane K Wherrett
  • Darrell M Wilson
  • Jeffrey P Krischer
  • Jay S Skyler
  • Linda Pickersgill
  • Eelco de Koning
  • Anette-G Ziegler
  • Bernhard Böehm
  • Klaus Badenhoop
  • Nanette Schloot
  • Jens Friis Bak
  • Paolo Pozzilli
  • Didac Mauricio
  • Marc Y Donath
  • Luis Castaño
  • Ana Wägner
  • Hans Henrik Lervang
  • Perrild, Hans
  • Mandrup-Poulsen, Thomas
  • Type 1 Diabetes TrialNet Canakinumab Study Group
Innate immunity contributes to the pathogenesis of autoimmune diseases, such as type 1 diabetes, but until now no randomised, controlled trials of blockade of the key innate immune mediator interleukin-1 have been done. We aimed to assess whether canakinumab, a human monoclonal anti-interleukin-1 antibody, or anakinra, a human interleukin-1 receptor antagonist, improved β-cell function in recent-onset type 1 diabetes.
Original languageEnglish
JournalLancet
Volume381
Issue number9881
Pages (from-to)1905-15
Number of pages11
ISSN0140-6736
DOIs
Publication statusPublished - 1 Jun 2013

    Research areas

  • Adolescent, Adult, Analysis of Variance, Antibodies, Monoclonal, C-Peptide, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Immunologic Factors, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Interleukin-1, Male, Treatment Outcome, Young Adult

ID: 96512501